Suven Life Sciences Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Suven Life Sciences Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than almost all Healthcare companies in India.
- Cash Locked Ratio: Money owed to suppliers is larger than money owed by customers plus stock: ₹65 per ₹100 of sales comes from others' credit, against ₹8 from others' credit three years earlier. Less money tied up than 98% of Healthcare companies in India.
- Steadiness Ratio: Sales grew in 1 of the last 3 years; profit grew in 1 of 3. Less steady than 94% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
−₹65Money owed to suppliers is larger than money owed by customers plus stock: ₹65 per ₹100 of sales comes from others' credit, against ₹8 from others' credit three years earlier.
Less money tied up than 98% of Healthcare companies in India.
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 94% of Healthcare companies in India.
Growth Efficiency Ratio
—Sales fell 47%
Sales fell 47% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-47% / +61%In 3 years sales changed by -47% while total assets changed by +61%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-66.3×Operating cash was negative last year, while some debt falls due within a year.
Lower than almost all Healthcare companies in India.
Cash Cushion Ratio
+2%Cash, after subtracting all debt, equals 2% of its market value (net cash).
Higher than 71% of Healthcare companies in India.
Tangible Assets Ratio
100%Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 91% of Healthcare companies in India.
Tangible Net Worth Ratio
100%Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 92% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Suven Life Sciences Limited made a loss over the last year. Suven Life Sciences Limited owes ₹0.05 for every ₹1 it owns. Suven Life Sciences Limited made a loss in each of the last two years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
LossSuven Life Sciences Limited made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
12.81The share price is 12.81 times Suven Life Sciences Limited's book value per share, higher than 91% of Healthcare companies in India.
Market cap
₹7,578 CrThe total market value of all of Suven Life Sciences Limited's shares at today's price (share price × number of shares), larger than 59% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹591 CrWhat Suven Life Sciences Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹20.93Net worth divided by the number of shares. The share price of ₹268.20 is 12.8 times this, which is the P/B above.
Return on equity (ROE)
-66.4%Suven Life Sciences Limited lost 66.4% of its shareholders' money over the last year, lower than almost all Healthcare companies in India.
Owes vs Owns
0.05×Suven Life Sciences Limited owes ₹0.05 for every ₹1 it owns (low), lower than almost all Healthcare companies in India.
Dividend yield
NoneSuven Life Sciences Limited does not currently pay a dividend.
Revenue growth
+7%Revenue rose 7% in the year to Mar 2026, and shrank 19% a year on average over 3 years.
Profit growth
LossSuven Life Sciences Limited made a loss in each of the last two years.
Profit margin
-3884.1%Suven Life Sciences Limited lost ₹3884 for every ₹100 of revenue.
Interest cover
Not coveredSuven Life Sciences Limited's operating profit did not cover its interest costs in the year to Mar 2026.
Cash vs debt
Net cashSuven Life Sciences Limited held ₹172 Cr more cash than debt (net cash) at Mar 2026.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Suven Life Sciences Limited: ₹7,578 Cr ÷ ₹591 Cr (31 Mar 2026) = 12.8.
What is Suven Life Sciences Limited's return on equity?
Suven Life Sciences Limited lost 66.4% of its shareholders' money over the last year, lower than almost all Healthcare companies in India.
How much does Suven Life Sciences Limited owe compared with what it owns?
Suven Life Sciences Limited owes ₹0.05 for every ₹1 it owns (low), lower than almost all Healthcare companies in India.
Does Suven Life Sciences Limited pay a dividend?
No. Suven Life Sciences Limited does not currently pay a dividend.
Is Suven Life Sciences Limited's revenue growing?
Revenue rose 7% in the year to Mar 2026, and shrank 19% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.